ZNTL - Zentalis Pharmaceuticals, Inc.
IEX Last Trade
4.22
0 0%
Share volume: 0
Last Updated: Fri 20 Dec 2024 09:21:02 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.46%
PREVIOUS CLOSE
CHG
CHG%
$4.22
-1.25
0.42%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-3.23%
1 Month
-5.66%
3 Months
-26.11%
6 Months
-36.84%
1 Year
-79.02%
2 Year
-84.20%
Key data
Stock price
$4.22
DAY RANGE
$2.97 - $4.22
52 WEEK RANGE
$2.86 - $18.07
52 WEEK CHANGE
-$79.18
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Kimberly L. Blackwell
Region: US
Website: zentalis.com
Employees: 160
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: zentalis.com
Employees: 160
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trials. The company has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC, GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.
Recent news